PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
50 hedge funds and large institutions have $60.1M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 12 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less funds holding
Funds holding: 60 → 50 (-10)
29% less capital invested
Capital invested by funds: $84.3M → $60.1M (-$24.2M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$682K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$622K |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$267K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 5 |
BlackRock
New York
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.77M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.46M |
| 3 |
Renaissance Technologies
New York
|
-$605K |
| 4 |
Millennium Management
New York
|
-$525K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$406K |
PHAS Hedge Fund Activity: Q3 2020 in Review
50 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q3 2020, worth a combined $60.1M — down 29% from $84.3M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PHAS and 3 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 18 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $682K. The largest seller was Wellington Management Group, cutting an estimated $2.77M.
- 50 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q3 2020, down from 60 in Q2 2020.
- Funds reported $60.1M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q3 2020, down 29% quarter-over-quarter.
- 3 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 12 closed out, a net change of -9 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Rock Springs Capital Management, an estimated $682K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Wellington Management Group, an estimated $2.77M sold.
Based on aggregated 13F filings for Q3 2020.